Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Rohto Pharmaceutical (4527)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3,036.0 +74.0    +2.50%
26/04 - Closed. Currency in JPY ( Disclaimer )
Type:  Equity
Market:  Japan
ISIN:  JP3982400008 
  • Volume: 1,047,400
  • Bid/Ask: 3,033.0 / 3,037.0
  • Day's Range: 2,942.0 - 3,070.0
Rohto Pharmaceutical 3,036.0 +74.0 +2.50%

4527 Income Statement

 
Featured here, the Income Statement (earnings report) for Rohto Pharmaceutical, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Income Statement
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Revenue 73294 66698 61171 62401
Revenue 73294 66698 61171 62401
Other Revenue, Total - - - -
Cost of Revenue, Total 29834 28510 25399 26415
Gross Profit 43460 38188 35772 35986
Total Operating Expenses 58997 57270 49632 57190
Selling/General/Admin. Expenses, Total 29163 28760 24233 17371
Research & Development - - - 11065
Depreciation / Amortization - - - -
Interest Expense (Income) - Net Operating -71 -63 -46 -53
Unusual Expense (Income) - - - -
Other Operating Expenses, Total 71 63 46 2392
Operating Income 14297 9428 11539 5211
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets -542 -134 - -300
Other, Net 813 -739 -702 748
Net Income Before Taxes 14026 10301 12241 4763
Provision for Income Taxes 4320 2729 2990 168
Net Income After Taxes 9706 7572 9251 4595
Minority Interest 5973 5859 5703 5508
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 9563 7504 9090 4740
Total Extraordinary Items - - - -
Net Income 9563 7504 9090 4740
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 9563 7504 9090 4740
Dilution Adjustment -0.756 -0.719 - -0.695
Diluted Net Income 9563.76 7504.72 9090 4740.69
Diluted Weighted Average Shares 228.8 228.8 228.79 228.8
Diluted EPS Excluding Extraordinary Items 41.8 32.8 39.73 20.72
DPS - Common Stock Primary Issue - 12 - 1
Diluted Normalized EPS 39.17 28.21 32.74 17.1
* In Millions of JPY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4527 Comments

Write your thoughts about Rohto Pharmaceutical
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email